BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Akeso’s AK-152 gains IND clearance in China for Alzheimer’s
To read the full story,
subscribe
or
sign in
.
Neurology/psychiatric
Akeso’s AK-152 gains IND clearance in China for Alzheimer’s
Nov. 17, 2025
No Comments
Akeso Inc. has received clearance from China’s National Medical Products Administration (NMPA) to initiate clinical trials with AK-152 for Alzheimer’s disease.
BioWorld Science
Regulatory
Neurology/psychiatric
Bispecific antibody
China
NMPA
